Bioavailability of a dexlansoprazole delayed-release orally disintegrating tablet: effects of food and mode of administration

References

• KatzPOGersonLBVelaMFGuidelines for the diagnosis and management of gastroesophageal reflux diseaseAm J Gastroenterol20131083308328 quiz 32923419381
   PubMed Web of Science ®Google Scholar
• DentJEl-SeragHBWallanderMAJohanssonSEpidemiology of gastro-oesophageal reflux disease: a systematic reviewGut200554571071715831922
   PubMed Web of Science ®Google Scholar
• Dexilant and Dexilant SoluTab [package insert]Deerfield, ILTakeda Pharmaceuticals America Inc2016
   Google Scholar
• SharmaPShaheenNJPerezMCClinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studiesAliment Pharmacol Ther200929773174119183157
   PubMed Web of Science ®Google Scholar
• MetzDCHowdenCWPerezMCLarsenLO’NeilJAtkinsonSNClinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitisAliment Pharmacol Ther200929774275419210298
   PubMed Web of Science ®Google Scholar
• PeuraDAMetzDCDabholkarAHParisMMYuPAtkinsonSNSafety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experienceAliment Pharmacol Ther200930101010102119735233
   PubMed Web of Science ®Google Scholar
• DabholkarAHHanCParisMMPerezMCAtkinsonSNPeuraDAThe 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux diseaseAliment Pharmacol Ther201133336637721118280
   PubMed Web of Science ®Google Scholar
• LeeRDVakilyMMulfordDWuJAtkinsonSNClinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibilityAliment Pharmacol Ther200929882483319243357
   PubMed Web of Science ®Google Scholar
• SoniesBCDalakasMCDysphagia in patients with the post-polio syndromeN Engl J Med199132417116211672011159
   PubMed Web of Science ®Google Scholar
• DanielsSKNeurological disorders affecting oral, pharyngeal swallowingGI Motility Online2006 http://www.nature.com/gimo/contents/pt1/full/gimo34.htmlAccessed January 1, 2017
   Google Scholar
• JaradehSMuscle disorders affecting oral and pharyngeal swallowingGI Motility Online2006 http://www.nature.com/gimo/contents/pt1/full/gimo35.htmlAccessed January 1, 2017
   Google Scholar
• SheehanNJDysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseasesRheumatology (Oxford)200847674675218326539
   PubMed Web of Science ®Google Scholar
• YanBMShafferEAEosinophilic esophagitis: a newly established cause of dysphagiaWorld J Gastroenterol200612152328233416688820
   PubMed Web of Science ®Google Scholar
• MaedaTNagataKSatohYYamazakiTTakanoDHigh prevalence of gastroesophageal reflux disease in Parkinson’s disease: a questionnaire-based studyParkinsons Dis2013201374212823476890
   PubMed Web of Science ®Google Scholar
• LockeGR3rdTalleyNJFettSLZinsmeisterARMeltonLJ3rdPrevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, MinnesotaGastroenterology19971125144814569136821
   PubMed Web of Science ®Google Scholar
• ChoSYChoungRSSaitoYAPrevalence and risk factors for dysphagia: a USA community studyNeurogastroenterol Motil201527221221925376877
   PubMed Web of Science ®Google Scholar
• CioconJOIndications for tube feedings in elderly patientsDysphagia199051152118023
   PubMedGoogle Scholar
• KukulkaMNudurupatiSPerezMCPharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazoleTherap Adv Gastroenterol201696759769
   Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research (CDER), US Department of Health and Human ServicesGuidance for Industry: Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs—General ConsiderationsRockville, MDFood and Drug Administration32014 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdfAccessed January 1, 2017
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research (CDER), US Department of Health and Human ServicesGuidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence StudiesRockville, MDFood and Drug Administration122002 Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdfAccessed January 1, 2017
   Google Scholar
• World Medical AssociationWorld Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjectsJAMA2013310202191219424141714
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human u. ICH harmonized tripartite guideline: guideline for Good Clinical PracticeJ Postgrad Med2001471455011590294
   PubMedGoogle Scholar
• FDAAA 801 Requirements ClinicalTrials.gov website [Updated November 2015]. Available from: https://clinicaltrials.gov/ct2/managerecs/fdaaaAccessed June 22, 2016
   Google Scholar
• Carnaby-MannGCraryMPill swallowing by adults with dysphagiaArch Otolaryngol Head Neck Surg20051311197097516301368
   PubMed Web of Science ®Google Scholar
• CzerniakRVakilyMWuJTAK-390MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled over applesauce or as an intact capsuleAm J Gastroenterol2008103S4S5 Abstract 12
   Web of Science ®Google Scholar
• MaaloufNDeveloping patient-centric drug formulations to meet patient needsBusiness Dev Licensing J20132014
   Google Scholar
• GrissingerMOral syringes: making better use of a crucial and economical risk-reduction strategyP T20133815623599662
   PubMedGoogle Scholar
• HuntRHArmstrongDJamesCEffect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteersAm J Gastroenterol200510091949195616128938
   PubMed Web of Science ®Google Scholar
• LindTRydbergLKylebackAEsomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux diseaseAliment Pharmacol Ther200014786186710886041
   PubMed Web of Science ®Google Scholar
• VakilyMZhangWWuJAtkinsonSNMulfordDPharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trialsCurr Med Res Opin200925362763819232037
   PubMed Web of Science ®Google Scholar